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Abstract 
Background 
The purpose of this study was to evaluate the efficacy of afatinib in EGFR-mutant metastatic NSCLC patients with 
acquired resistance to erlotinib or gefitinib. 
Materials and Methods 
We retrospectively analyzed the outcome of patients with EGFR-mutant advanced NSCLC treated with afatinib after 
failure of chemotherapy and EGFR TKIs. 
Results 
A total of 96 individuals were included in the study. According to EGFR status, most patients (n = 63; 65.6%) harbored 
a deletion in exon 19, and de novo T790M mutation was detected in 2 cases (T790M and exon 19). Twenty-four (25%) 
patients underwent repeated biopsy immediately before starting afatinib and secondary T790M was detected in 8 
(33%) samples. Among the 86 patients evaluable for efficacy, response rate was 11.6%, with a median progression 
free-survival (PFS) and overall survival (OS) of 3.9 and 7.3 months, respectively. No significant difference in PFS and OS 
was observed according to type of last therapy received before afatinib, type of EGFR mutation or adherence to 
Jackman criteria, and patients benefiting from afatinib therapy had longer PFS and OS (P < .001). Outcome results for 
repeated biopsy patients were similar to the whole population, with no evidence of response in T790M-positive 
patients. All patients were evaluable for toxicity, and 81% experienced an AE of any grade, with grade 3 to 4 AEs, 
mainly diarrhea and skin toxicity, occurring in 19 (20%) patients. 
Conclusion 
Our results showed that afatinib has only modest efficacy in a real life population of EGFR mutant NSCLC patients with 
acquired resistance to erlotinib or gefitinib. 
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 Introduction 
Epidermal growth factor receptor (EGFR)-activating mutations, mainly represented by deletion in exon 19 or the 
L858R substitution in exon 21, identified a distinct subgroup of non–small-cell lung cancer (NSCLC) with different 
prognosis and sensitivity to anti-tumor strategies.
1, 2 and 3
 Eight large randomized studies have clearly demonstrated the 
superiority of EGFR tyrosine kinase inhibitors (TKIs) in terms of response rate (RR), progression free-survival (PFS) and 
tolerability compared with conventional first-line platinum-doublet chemotherapy.
4, 5, 6, 7, 8, 9, 10 and 11
 Although no 
formal advantage in overall survival (OS) has emerged from the aforementioned studies, in all trials median survival 
was up to 2 to 3 years, indicating that EGFR-TKIs have changed natural history of EGFR-mutated NSCLC. Nevertheless, 
despite an initial dramatic tumor regression, after a median time of 9 to 12 months, all patients have disease 
progression due to the occurrence of resistance and the possibility of further control tumor growth inevitably 
decreases. 
From a practical point of view, the widespread use of EGFR-TKIs as first-line therapy translates to an undoubted 
clinical benefit for EGFR-mutant patients, but it also leads to the emergence of a novel clinical entity. Indeed, EGFR-
mutant patients with acquired resistance to EGFR TKIs represent a subgroup of individuals for whom approved 
treatment options are only modestly active and for whom there is an urgent need for novel targeted agents. So far, 
several mechanisms have been recognized as responsible for acquired resistance, with the secondary T790M 
mutation—a characteristic point mutation in the exon 20 of the EGFR gene—representing the most prominent, being 
detectable in more than 50% of patients exposed to gefitinib or erlotinib. 
12, 13 and 14
 
Afatinib (Giotrif) is an irreversible HER-family inhibitor and preclinical experience has demonstrated its activity in cell 
lines harboring EGFR mutations, including the T790M, thus suggesting a potential role in overcoming acquired 
resistance.
15 and 16
 In 2 trials, the LUX-Lung 1 and LUX-Lung 4,
17 and 18
 the role of afatinib was investigated at the daily 
dose of 50 mg in NSCLC patients resistant to EGFR TKIs defined according to the Jackman criteria,
19
 demonstrating 
similar results. RR ranged from 8% to 10%, with a PFS of nearly 4 months, in the whole population and in subgroup 
analyses. Nevertheless, in both studies there was no molecular restriction for patient selection, thus precluding the 
possibility to derive definitive conclusions on the role of afatinib in the EGFR-mutant and resistant population. 
The aim of the present study was to investigate the efficacy of afatinib in a real-life population of pretreated EGFR-
mutant NSCLC patients with acquired resistance to reversible EGFR TKIs. 
Materials and Methods 
Patient Selection 
In the present study we retrospectively analyzed the outcome of patients with EGFR-mutant advanced NSCLC treated 
with afatinib after failure of chemotherapy and reversible EGFR TKIs in 11 Italian institutions. Eligibility criteria 
included: availability of clinical information, such as demographic characteristics, presence of EGFR mutation, toxicity, 
and efficacy data of afatinib therapy. EGFR mutational status was assessed independently at each institution, 
according to the Società Italiana di Anatomia Patologica e Citopatologica Diagnostica guidelines and using direct 
sequencing (Sanger method), pyrosequencing, or real-time polymerase chain reaction (Therascreen EGFR29 RGQ PCR 
mutation kit, Qiagen, Venlo, Netherlands). 
20
 Afatinib was provided by Boehringer Ingelheim Inc as a compassionate 
use and self-administered at a 50-mg dose orally once daily continuously until disease progression, unacceptable 
toxicity, or patient refusal to continue. Dose reductions to 40 mg per day and then to 30 mg per day were considered 
on the basis of individual tolerability. Toxicities were assessed according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events version 3.0 every 4 weeks. In all patients, tumor assessment was performed 
every 2 months according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria
21
 and drug resupply 
was subordinated to tumor reassessment. Each center received the approval of the local ethics committee for each 
patient included in the study. All patients provided informed consent. 
Statistical Analysis 
A descriptive analysis on baseline characteristics was performed on the cohort of 96 EGFR-mutant lung cancer 
patients. RR was computed on 86 patients evaluable for efficacy. PFS was calculated from the time of starting therapy 
with afatinib to date of progression or last radiological assessment, and OS was calculated from the time of starting 
therapy with afatinib to death or last follow-up, with 95% confidence intervals using the Kaplan–Meier method. 
Differences in PFS or OS according to type of EGFR mutations, type of previous therapy, adherence to Jackman 
criteria, or response to afatinib therapy were evaluated using the Log rank test. The significance level for all analyses 
was set at P < .05. Statistical analysis was performed using SPSS version 20. 
Results 
Patient Characteristics 
A total of 96 consecutive subjects treated with afatinib between 2011 and 2013 were included in the study. Patient 
demographic and baseline characteristics are listed in Table 1.
19
 Most patients were female (n = 62; 64.4%), never 
smokers (n = 62; 64.4%), with an Eastern Cooperative Oncology Group performance status of 0 to 1 (n = 89; 92.8%) 
and treated with at least 3 or more therapy lines (n = 68; 70.8%). All patients had received previous EGFR TKI 
treatment such as gefitinib (n = 46; 47.9%), erlotinib (n = 46; 47.9%), or both (n = 4; 4.2%), as their first (n = 27; 28.1%), 
second (n = 57; 59.3%), or subsequent (n = 19; 19.7%) line of therapy. More than two-thirds of patients (n = 70; 72.9%) 
responded (complete response [CR] or partial response [PR]) to previous EGFR TKI therapy. Regarding therapy 
received before starting afatinib, 53.1% of patients (n = 51) received chemotherapy, and 41 (41.7%) fulfilled the 
Jackman criteria for acquired resistance. Seventeen patients (17.7%) received 1 or more subsequent lines of therapy 
after afatinib progression, including gefitinib in 35%. According to EGFR mutational status, 63 (65.6 %) patients 
harbored a mutation in exon 19, 25 (26.0%) in exon 21, 4 (4.2%) in exon 18, and 2 (2.1%) patients had an activating 
mutation not otherwise specified. De novo T790M mutation was detected in 2 (2.1%) patients and in both cases it was 
associated with mutation in exon 19. In 24 patients it was possible to perform a second biopsy immediately before 
starting afatinib treatment. Secondary T790M was detected in 8 (33%) samples, in 2 (8%) samples a novel EGFR 
mutation in exon 18 was detected, and 2 other (8%) resulted as wild type, and the remaining 12 (50%) samples 
displayed the same EGFR mutation detected at baseline. No additional biomarker was investigated. 
Table 1.  
Patient Characteristics (n = 96) 
Characteristic n % 
Median Age (Range) 62.0 (29.6-84.7) 
Men/Women 34/62 35.4/64.6 
Smoking History 
  
 Never/former 62/31 64.6/32.3 
 Current 3 3.1 
ECOG Performance Status 
  
 0/1/2/3 59/30/6/1 61.5/31.3/6.3/1.0 
Previous Chemotherapy Lines 
  
 1/2/3/>3 2/26/34/34 2.1/27.1/35.4/35.4 
Best Response to Previous Reversible EGFR-TKI 
  
 CR/PR/SD/PD 5/65/22/4 5.2/67.7/22.9/4.2 
Previous EGFR-TKI 
  
 Gefitinib/erlotinib/both 43/45/8 44.8/46.9/8.3 
Type of EGFR Mutation at Baseline 
  
 Exon 19 63 65.6 
 Exon 21 25 26.0 
 Exon 20 (T790M) 2 2.1 
 Exon 18 4 4.2 
 Not specified
a
 2 2.1 
Repeated Biopsy Immediately Before Starting Afatinib 
  
 Yes/No 24/72 25/75 
Characteristic n % 
EGFR Status in Repeated Biopsy 24 100 
 Same mutation of at baseline 12 50.0 
 EGFR wild type 2 8.3 
 EGFR mutated + T790M 8 33.4 
 Other EGFR mutation
b
 2 8.3 
Last Therapy Before Afatinib 
  
 EGFR-TKI 45 46.9 
 Chemotherapy 51 53.1 
Fulfilled the Jackman Criteria
19
 
  
 Yes/No 40/56 41.7/58.3 
Abbreviations: ECOG = Eastern Cooperative Oncology Group; EGFR = epidermal growth factor receptor; TKI = 
tyrosine kinase inhibitor. 
A Unknown means EGFR mutation not otherwise specified. 
B Only in exon 18. 
Efficacy 
Eighty-six patients were evaluable for response according to RECIST criteria (Table 2). Overall, 10 (11.6%) patients 
achieved confirmed response, including 1 CR and 9 PRs, and 38 (44.2%) obtained disease stabilization (SD) as their 
best response, with a disease control rate (CR + PR + SD) of 55.8%; furthermore, an additional 38 (44.2%) patients' 
disease progressed within the first 2 months of therapy. All responders had previously responded to reversible EGFR-
TKIs and for 70% of them chemotherapy was the last therapy received before afatinib. No difference in RR was 
detected in patients fulfilling Jackman criteria versus patients not fulfilling the same criteria (5% in both groups). 
Table 2.  
Response Rate in the Overall Population 
 Response Rate 
 
n % 
Evaluable Patients 86 100 
CR 1 1.1 
PR 9 10.5 
SD 38 44.2 
PD 38 44.2 
CR + PR 10 11.6 
CR + PR + SD 48 55.8 
All patients were assessable for PFS and OS. In the whole population, median PFS and OS were 3.9 (95% confidence 
interval [CI], 3.26-4.62) and 7.3 (95% CI, 4.03-10.69) months, respectively (Figure 1). No difference in PFS and OS was 
observed according to type of last received therapy (EGFR TKIs vs. chemotherapy), type of EGFR mutation (exon 19 vs. 
exon 21 vs. other) or adherence to Jackman criteria (Supplemental Table 1, Supplemental Figure 1, Supplemental 
Figure 2 and Supplemental Figure 3). As expected, a significant difference in PFS (7.1 months vs. 1.9 months; P < .001) 
and OS (13.4 months vs. 4.7 months; P < .001) was observed for patients benefiting from afatinib therapy ( Figure 2). 
 
 
 
 
 
 
 
 
 
 
Figure 1.  
(A) Kaplan–Meier Curve of Time to Progression-Free Survival and (B) Overall Survival in the Whole 
Population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  
(A) Kaplan–Meier Curve of Time to Progression-Free Survival and (B) Overall Survival According to Response 
to Afatinib 
Abbreviations: OS = Overall Survival; PFS = Progression-Free Survival. 
We further analyzed outcome in the subgroup of patients who received a repeated biopsy. This subgroup was 
representative of the whole population, with no difference in PFS (3.8 vs. 3.9 months; P = .5) or OS (10.3 vs. 7.3 
months; P = .2), as shown in Table 3. Among the 22 evaluable patients who receive a repeated biopsy, overall RR was 
4.5% (1 patient with PR), with SD of 45.4% and a progressive disease (PD) rate of 50%. Notably, none of the 6 
individuals harboring the T790M mutation responded, and the only responder had the less common mutation in exon 
18 in both tumor samples. 
Table 3.  
Outcome in Patients With Repeated Biopsy 
Pt ID 
EGFR Status At 
Baseline 
EGFR Status Before 
Afatinib 
Best Response to 
Afatinib 
PFS, 
Months 
OS, 
Months 
2 Exon 19 Exon 19 PD 2.00 14.85 
3 Exon 19 Exon 19 + T790M PD 1.54 16.99 
4 Exon 19 Exon 19 + T790M SD 15.41 19.16 
5 Exon 21 EGFR Wild type SD 7.49 18.76 
9 Exon 19 Exon 19 SD 3.48 6.44 
10 Exon 19 Exon 19 PD 1.68 6.67 
11 Exon 18 Exon 18 PR 7.89 13.74 
15 Exon 19 Exon 19 + T790M PD 1.97 2.14 
31 Exon 21 Exon 21 PD 7.23 19.39 
35 Exon 19 Exon 19 + T790M SD 2.27 5.32 
42 Exon 19 Exon 19 SD 8.97 13.14 
43 Exon 19 Exon 19 PD 1.74 6.64 
45 Exon 19 Exon 19 PD 1.97 2.89 
47 Exon 19 Exon 19 + T790M SD 8.08 9.50 
50 Exon 19 EGFR Wild type PD 1.84 6.70 
55 Exon 19 Exon 19 + T790M SD 3.81 3.91 
67 Exon 21 Exon 21 + T790M SD 5.13 10.35 
70 Exon 19 Exon 19 + T790M PD 1.18 2.50 
73 Exon 19 Exon 18 SD 1.61 1.91 
79 Exon 19 Exon 19 PD 3.78 3.94 
Pt ID 
EGFR Status At 
Baseline 
EGFR Status Before 
Afatinib 
Best Response to 
Afatinib 
PFS, 
Months 
OS, 
Months 
80 Exon 19 Exon 19 PD 1.28 1.31 
83 Exon 19 Exon 18 SD 4.07 14.16 
Overall 
  
RR, 4.5% PFS, 3.8 OS, 10.3 
Abbreviations: EGFR = epidermal growth factor receptor; OS = overall survival; PFS = progression-free 
survival; RR = response rate. 
Toxicity 
Ninety-five patients were assessable for toxicity and 77 (81.0%) subjects experienced a drug-related adverse event 
(AE) of any grade, including diarrhea and skin toxicity, this latter defined as skin rash/acneiform dermatitis, palmar-
plantar erythrodysesthesia syndrome, pruritus, xerosis, nail changes, and paronychia (Table 4). Grade 3 to 4 AEs 
occurred in 19 patients (20%), with diarrhea and skin toxicity as the most frequent events (10.6% and 11.6%, 
respectively); however, the occurrence of both types of adverse reactions was 5%. Other Grade 3 to 4 AEs included 
stomatitis in 1 patient and respiratory distress without clinical features of interstitial lung disease in another patient. 
Overall, 29 patients (30%) required a dose reduction to 40 mg (22%) and to 30 mg (8%) because of persistent Grade 2 
or 3 skin rash (24%), diarrhea (31%), or both (41%). Thirty patients (31.6%) had treatment delays because of toxicity, 
with only 3.2% of patients discontinuing afatinib because of unresolved AEs. 
Table 4.  
Most Common Treatment-Related AEs 
Toxicity 
All Grade 
 
Grade 3/4 
 
n % n % 
Evaluable Patients 95 100 95 100 
Total With Any Grade AEs 77 81.0 19 20.0 
Diarrhea 47 49.5 10 10.6 
Cutaneous Toxicity
a
 52 59.7 11 11.6 
Stomatitis 1 1.0 1 1.0 
Toxicity 
All Grade 
 
Grade 3/4 
 
n % n % 
Fatigue 2 2.1 0 0 
Respiratory Distress 1 1.0 1 1.0 
Abbreviation: AEs = adverse events. 
a Cutaneous toxicity included: skin rash/acneiform dermatitis, palmar-plantar erythrodysesthesia syndrome, 
pruritus, xerosis, nail changes, and paronychia. 
Discussion 
The present study, specifically conducted in EGFR-mutated NSCLCs with acquired resistance to erlotinib or gefitinib, 
showed that afatinib is effective only in a small fraction of NSCLC patients pretreated with reversible EGFR-TKIs. 
Epidermal growth factor receptor-mutant NSCLC represents a growing clinical entity for which efficacious therapeutic 
options are still lacking. In clinical practice, rechallenge with EGFR TKIs has been considered as a reasonable choice 
and clinical trials are currently under way to investigate such a strategy. In addition, several studies to evaluate 
retreatment with reversible EGFR-TKIs 
22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33
 or investigate the efficacy of irreversible EGFR 
TKIs 
17 and 18
 in the setting of acquired resistance to reversible inhibitors showed that there is a constant proportion of 
patients ranging up to 10% who continued to benefit from such an agent. 
17, 18, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33
 
Nevertheless, it is not possible to accurately predict which patients will further belong to this small subgroup. 
In our study, we reported a RR of 11%, quite similar to historical data
17, 18, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33
; more 
interestingly, we noted that in most cases, chemotherapy was the last therapy received before afatinib. Moreover, 
responding patients progressed later and lived longer than those who did not. Although this result seems too obvious, 
it reinforce the conviction that irrespective of mechanism responsible for erlotinib or gefitinib failure, reexposure to 
EGFR-TKIs after a break period could restore the sensitivity to driver inhibition probably because of the reexpansion of 
the initially sensitive clones. However, for the remaining 90% of our population, afatinib did not seem to produce any 
benefit, even when splitting results according to type of EGFR mutation or adherence to Jackman criteria. 
From a biological point of view, acquired resistance is a more complex phenomenon than a simple radiologic 
progression during treatment and a molecular definition should be mandatory, to allocate the correct patient to the 
correct treatment. Prolonged exposure to erlotinib or gefitinib provides selective pressure for the development of 
tumor clones able to grow irrespective of the drug inhibition. Some of the mechanisms underlying the phenomenon of 
secondary resistance are so far elucidated,
12, 13, 14, 34, 35, 36 and 37
 including the upregulation of the downstream signal by 
mesenchymal-epidermal transition amplification, EGFR amplification, phosphatidylinositol-3 kinase catalytic subunit 
alpha (PI3KCA) mutations, transition from epithelial to mesenchymal differentiation, and for a small percentage of 
resistant tumors, transformation into small-cell lung cancer. Furthermore, several studies recognized the emergence 
of the T790M EGFR gatekeeper mutation as most prominent, explaining approximately half of gefitinib/erlotinib 
treatment failures. 
12, 13, 14, 36 and 37
 
Because of its ability to arrest tumor growth in in vitro models of EGFR mutant clones resistant to gefitinib and 
harboring the T790M mutation, afatinib has emerged as the good candidate to test in the clinical setting of acquired 
resistance with a specific focus on T790M-mediated resistance. 
15, 16 and 37
 The combination of afatinib and cetuximab, a 
monoclonal antibody against EGFR, showed promising efficacy in patients with acquired resistance to EGFR TKIs with 
an increased risk of toxicity.
38
 Anecdotal series reported a potential efficacy of afatinib even in the presence of the 
T790M mutation. 
39 and 40
 Nevertheless, additional studies showed the lack of efficacy of the drug in patients with EGFR 
TKI acquired resistance. 
17 and 18
 The LUX-Lung 1 was a large phase III trial specifically designed to demonstrate the 
superiority of afatinib versus best supportive care in heavily pretreated NSCLC patients with secondary resistance to 
reversible EGFR TKIs. Although the study failed to meet its primary end point of OS, a modest but significant 
improvement in RR and PFS was observed for patients allocated in the active arm than in the placebo arm.
17
 Similarly, 
in the LUX-Lung 4, a phase II single-arm Japanese trial, RR and PFS were 8.2% and 4.4 months, respectively.
18
 Notably, 
in both trials there was not a molecular restriction for patient selection, even if the requirement for at least 12 weeks 
of previous EGFR TKI treatment was adopted as an enrichment strategy to increase the number of EGFR-mutated 
patients. As a consequence, archival tissues for EGFR assessment was available in a small percentage of patients, with 
only 6 cases (4 and 2 patients, in LUX-Lung 1 and LUX-Lung 4, respectively) carrying the T790M; in addiction, tumor 
samples were collected at the time of initial diagnosis rather than after erlotinib or gefitinib progression, thus 
precluding the possibility to postulate any hypothesis on the role of afatinib in presence of such a mutation. 
17 and 18
 
Although repeating tumor biopsy is not often feasible in NSCLC, in our cohort, a not negligible number of patients 
underwent repeated biopsy and we identified secondary T790M in 33% of cases, with no evidence of tumor response. 
It is interesting to note that 3 of these patients had a relative longer PFS; nevertheless, in such cases we cannot rule 
out a potential effect of the drug, even if the presence of T790M could be predictive for an indolent outcome.
36
 
These unmet expectations could be probably explained by the afatinib ability to inhibit not only the mutated EGFR but 
also the wild type protein, limiting the use of the optimal dose.
15 and 41
 Therefore, a new potentially effective strategy 
consists of the use of a new class of covalent irreversible EGFR inhibitors, sparing the EGFR wild type and effective 
only against the mutated form, including T790M. CO-1686 and AZD6162 are new third-generation EGFR TKIs and 
preliminary results of 2 recently presented phase I studies showed promising activity in a resistant setting with the 
absence of typical class-related AEs.
42 and 43
 
Taking into account all of these data suggested that the resistant setting is not the correct place to use afatinib. 
Furthermore, as shown in 2 recently published phase III trials conducted in more than 700 patients, the best 
performance is obtained when afatinib is used early in the course of disease.
10 and 11
 In LUX-Lung 3, the first trial to use 
the most fit comparator arm of cisplatin-pemetrexed, patients treated with afatinib had a 42% relative reduction in 
risk of progression compared with those who received standard chemotherapy.
10
 Again, treatment with the EGFR TKI 
was also associated with greater RR and a better toxicity profile than chemotherapy, although Grade 3 diarrhea and 
skin rash occurred in 14% and 16% of cases receiving the experimental drug, respectively. The second trial, the LUX-
Lung 6, in which afatinib was compared with standard doublet of cisplatin-gemcitabine in an Asian population, 
replicated these findings. Treatment with afatinib doubled PFS, tripled RR, and it was responsible for a 35.6% of Grade 
3 to 4 drug-related AEs, mainly diarrhea and skin rash.
11
 
At this proposal, it is a general opinion that afatinib is more toxic than the first-generation TKIs, erlotinib and gefitinib. 
In the metastatic setting, the preservation of quality of life still remains one of the goals of therapy, mainly in second 
and subsequent lines of treatment. Moreover, regarding safety profile, our findings were consistent with the well 
known toxicity profile of afatinib.
10, 11, 17 and 18
 In our series we reported an overall incidence of any grade AEs of 81%, 
quite similar to those described in all afatinib trials.
10, 11, 17 and 18
 Furthermore, Grade 3 to 4 AEs, mainly diarrhea and 
skin rash, occurred in 20% of subjects. This percentage was not unexpected, probably because we used as a starting 
dose 50 mg, instead of the recommended 40 mg dose.
10 and 11
 Nevertheless, only 3% of patients discontinued afatinib 
because of unresolved toxicity, thus suggesting that, with appropriate dose reduction and adequate supportive care, 
afatinib was manageable also in a cohort of heavily pretreated patients. 
Conclusion 
Our results showed that afatinib has only modest efficacy in a real-life population of EGFR-mutant NSCLCs with 
acquired resistance to erlotinib or gefitinib and its use in EGFR-mutant patients should be reserved for EGFR TKI naive 
individuals. Third-generation irreversible EGFR TKIs seem to offer important advantages over older compounds, 
especially in the management of resistant tumors, and confirmatory trials are urgently awaited. 
Clinical Practice Points 
•In EGFR-mutant NSCLC patients, 8 randomized studies have clearly demonstrated the superiority of EGFR-TKIs in 
terms of outcome and tolerability compared with standard first-line platinum-doublet chemotherapy. 
•Currently, the approved treatment options in EGFR-mutant patients with acquired resistance to first-generation 
EGFR TKIs are only modestly active and there is an urgent need for novel targeted agents. 
•Afatinib is a second-generation irreversible HER-family inhibitor and preclinical models suggest a potential role in 
overcoming acquired resistance, including secondary T790M mutation. 
•In patients with acquired resistance to EGFR TKIs, no study has been specifically focused on individuals with EGFR 
mutations, precluding the possibility to derive definitive conclusions on the role of this drug in resistant cases. 
•In our study, we retrospectively evaluated the outcome of 96 EGFR mutant NSCLC patients treated with afatinib after 
failure of chemotherapy and EGFR TKI treatments. Our data showed that afatinib was effective only in a small fraction 
of NSCLC patients with acquired resistance to EGFR TKIs. 
•Afatinib treatment should be reserved only for EGFR–TKI-naive EGFR-mutant NSCLC patients. 
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Supplemental Figure 1.  
(A) Kaplan–Meier Curve of Time to Progression-Free Survival (PFS) and (B) Overall Survival (OS) According to 
Therapy Received Before Afatinib 
Abbreviations: EGFR = Epidermal Growth Factor Receptor; TKI = Tyrosine Kinase Inhibitor. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 2.  
(A) Kaplan–Meier Curve of Time to Progression-Free Survival (PFS) and (B) Overall Survival (OS) According to 
Type of EGFR Mutation 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 3.  
(A) Kaplan–Meier Curve of Time to Progression-Free Survival (PFS) and (B) Overall Survival (OS) According to Jackman 
Criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 1.  
Outcome Results in Subgroup Analyses 
 
 
Last Therapy Before Afatinib 
 
Type of Mutation 
 
Fulfilled Jackman Criteria 
 
CT EGFR-TKI Exon 19 Exon 21 (and Other) Yes No 
Patients, n 51 45 63 33 40 56 
PFS, Months 4.0 3.9 3.4 4.9 3.9 3.8 
 95% CI 3.18-4.83 2.75-5.12 2.48-4.47 3.22-6.63 2.67-5.20 2.80-4.81 
 P .4 .3 .9 
OS, Months 6.7 8.1 7.3 7.3 8.1 6.7 
 95% CI 3.67-9.72 2.96-13.27 3.06-11.66 2.42-12.30 3.32-12.91 3.57-9.83 
 P .7 .8 .6 
Abbreviations: CT = chemotherapy; EGFR = epidermal growth factor receptor; OS = overall survival; PFS = progression-
free survival; TKI = tyrosine kinase inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
1 
T.J. Lynch, D.W. Bell, R. Sordella, et al. 
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer 
to gefitinib 
N Engl J Med, 350 (2004), pp. 2129–2139 
2 
J.G. Paez, P.A. Jänne, J.C. Lee, et al. 
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy 
Science, 304 (2004), pp. 1497–1500 
3 
C. Gridelli, F. de Marinis, F. Cappuzzo, et al. 
Treatment of advanced non–small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK 
gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology 
Clin Lung Cancer, 15 (2014), pp. 173–181 
4 
T.S. Mok, Y.L. Wu, S. Thongprasert, et al. 
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma 
N Engl J Med, 360 (2009), pp. 947–957 
5 
J.Y. Han, K. Park, S.W. Kim, et al. 
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with 
adenocarcinoma of the lung 
J Clin Oncol, 30 (2012), pp. 1122–1128 
6 
T. Mitsudomi, S. Morita, Y. Yatabe, et al. 
Gefitinib versus cisplatin plus docetaxel in patients with non–small-cell lung cancer harbouring mutations of the 
epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial 
Lancet Oncol, 11 (2010), pp. 121–128 
7 
M. Maemondo, A. Inoue, K. Kobayashi, et al. 
Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR 
N Engl J Med, 362 (2010), pp. 2380–2388 
8 
C. Zhou, Y.L. Wu, G. Chen, et al. 
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non–small-
cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study 
Lancet Oncol, 12 (2011), pp. 735–742 
9 
R. Rosell, E. Carcereny, R. Gervais, et al. 
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-
positive non–small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial 
Lancet Oncol, 13 (2012), pp. 239–246 
10 
L.V. Sequist, J.C. Yang, N. Yamamoto, et al. 
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR 
mutations 
J Clin Oncol, 31 (2012), pp. 3327–3334 
11 
Y.L. Wu, C. Zhou, C.P. Hu, et al. 
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non–small-cell lung 
cancer harboring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial 
Lancet Oncol, 15 (2014), pp. 213–222 
12 
L.V. Sequist, A.W. Waltman, D. Dias-Santagata, et al. 
Genotyping and histological evolution of lung cancers acquiring resistance to EGFR inhibitors 
Sci Transl Med, 3 (2011), p. 75ra26 
13 
W. Pao, V.A. Miller, K.A. Politi, et al. 
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR 
kinase domain 
PLoS Med, 2 (2005), p. e73 
14 
M.E. Arcila, G.R. Oxnard, K. Nafa, et al. 
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M 
mutation using a locked nucleic acid-based assay 
Clin Cancer Res, 17 (2011), pp. 1169–1180 
15 
D. Li, L. Ambrogio, T. Shimamura, et al. 
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models 
Oncogene, 27 (2008), pp. 4702–4711 
16 
E.L. Kwak, R. Sordella, D.W. Bell, et al. 
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib 
Proc Natl Acad Sci U S A, 102 (2005), pp. 7665–7670 
 
17 
V.A. Miller, V. Hirsh, J. Cadranel, et al. 
Afatinib versus placebo for patients with advanced, metastatic non–small-cell lung cancer after failure of erlotinib, 
gefitinib, or both, and one or two lines of chemotherapy (LUX- Lung 1): a phase 2b/3 randomised trial 
Lancet Oncol, 13 (2012), pp. 528–538 
18 
N. Katakami, S. Atagi, K. Goto, et al. 
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non–small-cell lung cancer who progressed during 
prior treatment with erlotinib, gefitinib, or both 
J Clin Oncol, 31 (2013), pp. 3335–3341 
19 
D. Jackman, W. Pao, G.J. Riely, et al. 
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-
cell lung cancer 
J Clin Oncol, 28 (2010), pp. 357–360 
20 
A. Marchetti, N. Normanno, AIOM - SIAPEC-IAP, et al. 
Recommendations for mutational analysis of EGFR in lung carcinoma 
Pathologica, 102 (2010), pp. 119–126 
21 
P. Therasse, S.G. Arbuck, E.A. Eisenhauer, et al. 
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and 
Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada 
J Natl Cancer Inst, 92 (2000), pp. 205–216 
22 
S. Watanabe, J. Tanaka, T. Ota, et al. 
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non–small-cell lung cancer patients who benefited 
from prior effective gefitinib therapy: a retrospective analysis 
BMC Cancer, 11 (2011), p. 1 
23 
H. Asahina, S. Oizumi, A. Inoue, et al. 
Phase II study of gefitinib readministration in patients with advanced non–small-cell lung cancer and previous 
response to gefitinib 
Oncology, 79 (2010), pp. 423–429 
24 
I.J. Oh, H.J. Ban, K.S. Kim, et al. 
Retreatment of gefitinib in patients with non–small-cell lung cancer who previously controlled to gefitinib: a single-
arm, open-label, phase II study 
Lung Cancer, 77 (2012), pp. 121–127 
25 
H. Yokouchi, K. Yamazaki, I. Kinoshita, et al. 
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non–small-cell lung cancer 
BMC Cancer, 7 (2007), p. 51 
26 
A. Becker, L. Crombag, D.A. Heideman, et al. 
Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially 
responded to EGFR-TKI treatment 
Eur J Cancer, 47 (2011), pp. 2603–2606 
27 
B.C. Cho, C.K. Im, M.S. Park, et al. 
Phase II study of erlotinib in advanced non–small-cell lung cancer after failure of gefitinib 
J Clin Oncol, 25 (2007), pp. 2528–2533 
28 
Z. Song, X. Yu, C. He, et al. 
Re-administration after the failure of gefitinib or erlotinib in patients with advanced non–small-cell lung cancer 
J Thorac Dis, 5 (2013), pp. 400–405 
29 
Z.T. Zhou, X.H. Xu, Q. Wei, et al. 
Erlotinib in advanced non–small-cell lung cancer after gefitinib failure 
Cancer Chemother Pharmacol, 64 (2009), pp. 1123–1127 
30 
A. Hata, N. Katakami, H. Yoshioka, et al. 
Erlotinib after gefitinib failure in relapsed non–small-cell lung cancer: clinical benefit with optimal patient selection 
Lung Cancer, 74 (2011), pp. 268–273 
31 
D.H. Lee, S.W. Kim, C. Suh, et al. 
Phase II study of erlotinib as a salvage treatment for non–small-cell lung cancer patients after failure of gefitinib 
treatment 
Ann Oncol, 19 (2008), pp. 2039–2042 
32 
D.B. Costa, K.S. Nguyen, B.C. Cho, et al. 
Effects of erlotinib in EGFR-mutated non–small-cell lung cancers with resistance to gefitinib 
Clin Cancer Res, 14 (2008), pp. 7060–7067 
33 
A.S. Wong, R. Soong, S.B. Seah, et al. 
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non–
small-cell lung cancer 
J Thorac Oncol, 3 (2008), pp. 400–404 
34 
J.A. Engelman, K. Zejnullahu, T. Mitsudomi, et al. 
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling 
Science, 316 (2007), pp. 1039–1043 
35 
J. Bean, C. Brennan, J. Shih, et al. 
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to 
gefitinib or erlotinib 
Proc Natl Acad Sci U S A, 104 (2007), pp. 20932–20937 
36 
G.R. Oxnard, M.E. Arcila, C.S. Sima, et al. 
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients 
with tumors harboring the T790M mutation 
Clin Cancer Res, 17 (2011), pp. 1616–1622 
37 
C.H. Yun, K.E. Mengawasser, A.V. Toms, et al. 
The T790M mutation in the EGFR kinase causes drug resistance by increasing the affinity for ATP 
Proc Natl Acad Sci U S A, 105 (2008), pp. 2070–2075 
38 
Y.Y. Janjigian, H.J. Groen, L. Horn, et al. 
Activity and tolerability of afatinib (BIBW2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib 
or gefitinib (abstract) 
J Clin Oncol, 29 (2011) 482s (abstract 7525) 
39 
J.M. Sun, M.J. Ahn, Y.L. Choi, et al. 
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors 
Lung Cancer, 82 (2013), pp. 294–298 
40 
P. Bordi, M. Tiseo, B. Bortesi, et al. 
Overcoming T790M-acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report 
Tumori, 100 (2014), pp. 20e–23e 
41 
T.A. Yap, L. Vidal, J. Adam, et al. 
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors 
J Clin Oncol, 28 (2010), pp. 3965–3972 
42 
L.V. Sequist, J.C. Soria, S. Gadgeel, et al. 
First-in human evaluation of CO-1686, an irreversible highly selective tyrosine kinase inhibitor of mutations of EGFR 
(activating and T790M) (abstract) 
J Clin Oncol, 32 (2014) 5s (abstract 8010) 
43 
P.A. Janne, S.S. Ramalingam, J.C. Yang, et al. 
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non–
small-cell lung cancer (NSCLC) (abstract) 
J Clin Oncol, 32 (2014) 5s (abstract) 
 
